Skip to main content

Table 2 The crude incidence rate of malignancies in patients with SLE

From: Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea

Type of malignancy Total (n=17,854) Female (n=16,143) Male (n=1711)
No. of cases Incidence per
10,000 PYs (95% CI)
No. of cases Incidence per
10,000 PYs (95% CI)
No. of cases Incidence per
10,000 PYs (95% CI)
Overall malignancies 836 138.16 (128.79, 147.52) 738 134.45 (124.75, 144.15) 98 174.40 (139.87, 208.93)
Solid malignancy 768 126.92 (117.94, 135.90) 686 124.97 (115.62, 134.33) 82 145.93 (114.34, 177.51)
 Breast and reproductive system 175 28.92 (24.64, 33.21) 164 29.88 (25.30, 34.45) 11 19.58 (8.01, 31.14)
 Thyroid 154 25.45 (21.43, 29.47) 148 26.96 (22.62, 31.31) 6 10.68 (2.13, 19.22)
 Liver 63 10.41 (7.84, 12.98) 55 10.02 (7.37, 12.67) 8 14.24 (4.37, 24.10)
 Colon 61 10.08 (7.55, 12.61) 51 9.29 (6.74, 11.84) 10 17.80 (6.77, 28.83)
 Lung 34 5.62 (3.73, 7.51) 25 4.55 (2.77, 6.34) 9 16.02 (5.55, 26.48)
 Pancreas 32 5.29 (3.46, 7.12) 29 5.28 (3.36, 7.21) 3 5.34 (0, 11.38)
 Stomach 31 5.12 (3.32, 6.93) 27 4.92 (3.06, 6.77) 4 7.12 (0.14, 14.09)
 Bladder 12 1.98 (0.86, 3.11) 10 1.82 (0.69, 2.95) 2 3.56 (0, 8.49)
 Head and neck 11 1.82 (0.74, 2.89) 9 1.64 (0.57, 2.71) 2 3.56 (0, 8.49)
 Kidney 10 1.65 (0.63, 2.68) 5 0.91 (0.11, 1.71) 5 8.90 (1.10, 16.70)
 Biliary tract 7 1.16 (0.30, 2.01) 4 0.73 (0.01, 1.44) 3 5.34 (0, 11.38)
 Brain and central nervous system 5 0.83 (0.10, 1.55) 5 0.91 (0.11, 1.71) 0 NC
 Larynx 2 0.33 (0, 0.79) 2 0.36 (0, 0.87) 0 NC
Haematology malignancy 68 11.24 (8.57, 13.91) 52 9.47 (6.90, 12.05) 16 28.47 (14.52, 42.43)
 Non-Hodgkin lymphoma 36 5.95 (4.01, 7.89) 27 4.92 (3.06, 6.77) 9 16.02 (5.55, 26.48)
 Multiple myeloma 14 2.31 (1.10, 3.53) 13 2.37 (1.08, 3.66) 1 1.78 (0, 5.27)
 Leukaemia 12 1.98 (0.86, 3.11) 8 1.46 (0.45, 2.47) 4 7.12 (0.14, 14.09)
 Hodgkin lymphoma 3 0.50 (0, 1.06) 3 0.55 (0, 1.16) 0 NC
  1. PY, person-year; CI, confidence interval; NC, not calculated